ERBITUX PI PDF

treated with Erbitux and radiation therapy and in 3% of patients Limitation of Use: Erbitux is not indicated for treatment of K-Ras mutation- positive colorectal. Each mL of solution for infusion contains 5 mg cetuximab. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck All sections. PI reformatted.

Author: Gam Vudojora
Country: Spain
Language: English (Spanish)
Genre: Photos
Published (Last): 23 January 2018
Pages: 453
PDF File Size: 4.14 Mb
ePub File Size: 2.46 Mb
ISBN: 661-3-76422-442-9
Downloads: 98578
Price: Free* [*Free Regsitration Required]
Uploader: Shajas

Raxibacumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Raxibacumab. Landogrozumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Landogrozumab. Radiotherapy plus Erbitux for squamous-cell carcinoma of the head and neck.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Robatumumab.

Milatuzumab Ergitux risk or severity of adverse effects can be increased when Cetuximab is combined with Milatuzumab. Pembrolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Pembrolizumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with AMG Impact of EGFR expression on colorectal cancer patients prognosis and survival. Untangling the ErbB signaling network. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Cetuximab.

The risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab. Despite the positive results for the secondary endpoints, however, the primary study point, overall survival, was not met. Obinutuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Obinutuzumab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Besilesomab.

  DANIEL GUERIN NO GODS NO MASTERS PDF

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line [letter] J Clin Oncol. Nonetheless, the toxicity profile of cetuximab does not overlap with that of cytotoxic agents, making it an appealing agent for use in combination regimens. Complete tumor regression was achieved in 5 patients, with only microfoci within fibrotic tissue found in 6 others.

Development of hypomagnesemia may be related to inhibition of EGFR in the kidneys, although it may also be a consequence of diarrhea Lenz Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. The risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin. The risk or severity of adverse effects can be increased when Cetuximab is combined with Blosozumab.

Head, Neck, and Colorectal Cancer Treatment | ERBITUX (cetuximab)

Blinatumomab The risk or severity of adverse effects can be increased when Cetuximab is combined with Blinatumomab.

Basiliximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Basiliximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Brodalumab. Apolizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Apolizumab.

Bivatuzumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Bivatuzumab. Ibalizumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ibalizumab.

Cunningham et al b. Siltuximab Erbitxu risk or severity of adverse effects can be increased when Cetuximab is combined with Siltuximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Teprotumumab.

  DERECHO ROMANO ALDO TOPASIO FERRETTI PDF

TGA eBS – Product and Consumer Medicine Information

The eerbitux or severity of adverse effects can be increased when Cetuximab is combined with Labetuzumab. Tarextumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Tarextumab.

Epimestrol Epimestrol may increase the thrombogenic activities of Cetuximab. The risk or severity of adverse effects can be increased when Cetuximab is combined with Gevokizumab.

This site is intended for US residents ages 18 and over. Glembatumumab vedotin The risk or severity of adverse effects can be increased when Cetuximab is combined with Glembatumumab vedotin. Cetuximab therapy and symptomatic hypomagnesemia. As the erbiitux trials discussed above have shown, the refinement of patient selection is one area in the clinical development of cetuximab that still requires further study. Adding cetuximab to first-line mCRC treatment Building upon the effectiveness of cetuximab in refractory mCRC, several studies have also been conducted to explore pj adding cetuximab to first-line therapy would improve patient outcome Table 2.

Cetuximab in the management of colorectal cancer

The following adverse reactions have been identified during post approval use of Erbitux. Evolocumab The risk or severity of adverse effects can be increased when Cetuximab is combined with Evolocumab. Use of cetuximab in patients with Ras mutations resulted in no clinical benefit with treatment related toxicity.